The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

The market didn't appreciate Amgen's (NASDAQ: AMGN) latest clinical data update, with the biopharma's shares falling more ...

Eli Lilly & Co. closed $177.18 short of its 52-week high ($972.53), which the company reached on August 22nd. Supported by ...

After 10 long years, the company that has developed a collagen biomaterial to help heal tissue is readying itself for its ...

The ESMP platform enables marketing authorisation holders to report shortages and will be mandatory from 2025.